Introduction: Polyradiculoneuropathy is a post infectious or immune mediated peripheral nerve disorder. It is a clinically heterogeneous group with either acute or chronic course, axonal or demyelinating, motor or sensory nerve damage. Acute forms are known under eponym GuillainBarré syndrome (GBS). Relapsing or slowly progressive course is a feature of chronic inflammatory demyelinating polyneuropathy (CIDP). The aim of our study was to analyze clinical features, laboratory characteristics (cerebrospinal fluid, antiganglioside antibodies), electrophysiological findings and patients' outcome. Methods: Our hospital database was searched from 2002 to 2012 for patients with GBS and CIDP and was analyzed according to our aim. Results: Ninety-eight patients were included in our study, 76 (78%) with GBS and 22 (22%) with CIDP. Major characteristics are shown in table 1. Sensory symptoms and pain were equally present in both groups; weakness and disability were more prominent in GBS patients. Six (6%) patients had Miller-Fischer syndrome; 5 were tested for anti GQ1b and 4 were positive. Presence of antiganglioside antibodies was not related to bad outcome after 18 months (Modified Rankin Scale 4-6). Age ≥65 years and axonal damage were predictors of worse outcome after 18 months (p=0.026 and p=0.04 respectively). A need for ventilatory support was not related to bad outcome. Conclusions: Higher age and signs of axonal damage are bad prognostic factors in GBS. Antiganglioside antibodies screening might have some diagnostic but no prognostic value in GBS patients. Proper intensive care is needed to prevent additional mortality from complications of severe initial disability. Domino liver transplantation (DLT) increase the number of grafts available to treat patients with liver disease. But, this procedure has a risk of transmission of systemic transthyretin (TTR) amyloidosis. A 69-year-old FAP male patient whose complaints started 8 years after DLT was evaluated because of numbness and burning sensation of feet and hands, walking difficulty, dizziness, diarrhea, dry mouth, urinary retention. His neurological examination showed distal weakness of all limbs with bilateral steppage gait, stocking and glove type hypoesthesia and hypoalgesia, diminished vibration sensation and absent tendon reflexes. According to these findings his clinical disease stage was classified as I and his neurological disability score (NDS) 68. EMG showed findings consistent with distal sensory motor axonal polyneuropathy accompanied by autonomic involvement. His sural nerve biopsy disclosed severe axon loss with amyloid deposition. He did not have any cardiac, renal or eye involvement due to amyloidosis. He refused to undergo a new liver transplantation and was put under treatment with Tafamidis Meglumine (Vyndaqel). He is still receiving the treatment that started seven months ago. He became stable and his sensory symptoms showed slight improvement. Although estimated time of de novo amyloidosis transfer risk is expected to be minimum 20 years, according to the literature patients can become symptomatic earlier than expected. Our patient's signs and symptoms started 7 years after transplantation. We do not yet know the effects of the Tafamidis treatment in these patients. Disclosure: Nothing to disclose
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Acute bilateral non-traumatic radial nerve palsy -rare presentation, uncertain etiology Introduction: Acute transient radial nerve palsies usually have a traumatic/compressive etiology. Occasionally, no such mechanism of lesion is verified and a bilateral presentation is even rarer. Methods: We present a case of a 63-year-old female patient, observed at emergency department. Three days before, she had noticed left hand extension weakness, followed, in the next day, by right hand extension weakness. The establishment time in each side was brief (hours). She had no other motor or sensory complaint. She had controlled hypertension and hypothyroidism, and used to have frequent artistic hobbies using lead-containing dyes and ceramics. Results: Apart from bilateral wrist and fingers extension paresis (MRC 1-2/5), her neurological examination was unremarkable. Blood analysis, immunological studies, serologies, C-reactive protein and sedimentation-rate were normal or negative. The serum-lead levels were within normal limits; however urinary-lead levels were 91,73 micromol/day (normal 0.00-0.39). She performed neurophysiological tests, 15 days after palsy-onset: i)nerve conduction studies were normal, including motor and sensory radial potentials; ii)needle EMG revealed fibrillations and positive-sharp waves, at rest, and reduced number of motor unit potentials, during voluntary activity, in common extensor digitorum, brachioradialis and triceps muscles, bilaterally. She has avoided contact with leadcontaining substances. Five months later, without any specific treatment, she was fully recovered. Conclusions: This presentation is rarely described in the literature. Although serum-lead level was negative, the high urinary-lead level could suggest some pathophysiologic involvement of this metal, in this case. Additionally, an underlying genetic susceptibility or immunological condition cannot be excluded. Disclosure: Nothing to disclose Subcutaneous is better tolerated than intravenous immunoglobulin treatment: the experience with two CIDP patients E. Pasini, R. Liguori, P. Avoni, V. Donadio
IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy
Introduction: Treatment with intravenous immunoglobulin (IVIg) is commonly used in patients with autoimmune neuropathy with good results but may show adverse effects partially limiting its use. Here we report our experience with two patients showing chronic inflammatory demyelinating polyneuropathy (CIDP) treated with IVIg who needed to shift to subcutaneous immunoglobulin (SCIg) because of considerable adverse events. Methods: The first patient was a 48-year-old man who started after CIDP diagnosis a 5 days of high dosage IVIg (0.4 mg/Kg/die) and a maintenance IVIg cycle (3 days) every 4-5 months.The second patient was a 70-year-old man affected by CIDP starting IVIg at high dosage (0.4 mg/ Kg/die for 5 days). After the treatment neurological examination showed a motor and sensory improvement in both patients. Results: IVIg although producing a significant improvement of neurological symptoms was stopped in both patients because of a disabling symptoms such as a "tension-type headache" limiting work activities in the first patients or a lower limb venous thrombosis with subsequent pulmonary embolism after the first IVIg cycle in the second patient. The shift to SCIG (Hizentra: 8 gr/week) produced no change at the neurological examination compared to IVIg without any side effects after 8-12 months. Importantly after SCIG they reported an improvement of quality of life as evaluated by a short Form Health Survey scale (SF-36). Conclusions: SGIG treatment was effective as such as IVIg but it was better tolerate without any relevant side effects and with higher quality of life. Disclosure: Nothing to disclose
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Posterior interosseous neuropathy -a diagnostic challenge 
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Search for autoantibodies targeting the nodes of Ranvier in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Introduction: Nodal, paranodal and juxtaparanodal proteins have been the focus of ongoing research as potential antigens in both central and peripheral demyelinating disorders. Antibodies against contactin-2, which assists in the formation of axonal connections, have been detected in multiple sclerosis patients (Derfuss, PNAS 2009; 106, 8302) and polymorphisms in the gene encoding contactin-2 may influence treatment response in CIDP (Iijima, Neurology 2009; 73, 1348) . Cx32, which comprises gap junctions of the paranode, is also a potential target antigen in PNS demyelination as mutations in Cx32 cause Charcot-Marie-Tooth disease. Our objective was to examine whether CIDP patients harbour antibodies against antigens expressed at the nodes of Ranvier such as contactin-2/TAG1 and Cx32. Methods: Sera from 45 patients with CIDP (with paired CSF samples from two), 5 with multifocal motor neuropathy (MMN), and 4 with combined CIDP and central demyelination (with paired CSF from one) were examined. We established a cell-based assay (CBA), in which human embryonic kidney cells were transfected with cDNA clones encoding either the FNIII or the IgC2 domains of TAG-1 or CX32, all tagged with eGFP. Antibodies against IgC2 and Cx32 were used as positive controls. Antibody binding was visualized using an anti-human fluorescent secondary antibody. Results: No positive staining was detected in any of the patients with autoimmune peripheral neuropathies for both antigens. Conclusions: Contactin-2 and Cx32, which is responsible for a genetic demyelinating neuropathy, are not autoantibody targets in aquired autoimmune demyelinating neuropathies. Reactivity to other nodal, paranodal or juxtaparanodal antigens is currently explored. Disclosure: Nothing to disclose Introduction: Our aim was to determine the distinguishing features of two cases of sensory mononeuritis who presented with similar clinical, electrophysiological and past medical history features. Methods: We systematically reviewed the clinical features, laboratory studies, neurophysiologic findings, and histopathological changes of two patients with sensory mononeuritis. In one, the final diagnosis was pure neural leprosy (PNL) and the other non-systemic vasculitic neuropathy (NSVN). Results: Our patients were females who had resided in areas endemic for leprosy (Brazil). They both developed a progressive, purely sensory, painful mononeuritis distally in the lower limbs followed, in patient 1, by asymmetric ankle edema and nodular induration without skin changes. In both cases, sensory nerve potentials were asymmetrically reduced in amplitude, and sural nerve biopsy revealed nonspecific inflammatory infiltration of the vasa nervosum in the epi-and perineurium. An axonal neuropathy, granulomas with epithelioid cells and caseous necrosis were observed in patient 1 confirming paucibacillary PNL; a skin punch biopsy revealed similar changes. Multifocal axonodemyelinating changes in patient 2 were compatible with NSVN. Both patients improved following targeted treatment (rifampicin and dapsone in case 1 and rituximab in case 2). Conclusions: Both patients were surprisingly homogeneous in their clinical and electrophysiological manifestations. Late appearance of edema and nodular induration in the vicinity of affected nerves, as well as, distinct pathological features with granulomas and caseous necrosis in skin or nerve biopsies appeared to be the cardinal features distinguishing PNL from NSVN. Disclosure: Nothing to disclose Introduction: The first line treatment for chronic hepatitis C is the combination of PEG-IFN and Ribavirin. There are a few reports of acute inflammatory demyelinating polyneuropathy (AIDP) as a neurological side effect of this therapy. Psychiatric side effects such as depressive disorders, panic attacks and mental status abnormalities are likely to appear during immunomodulating therapy but also in the course of AIDP. Results: We report the case of a 59-years-old woman treated with PEG-IFN and Ribavirin for 21 weeks for a chronic HCV infection that developed Guillain-Barré Syndrome (GBS) and acute psychosis. The patient was admitted in our department with distal rapid progressive paresthesias in her arms and feet, associating weakness, numbness, as well as intense pain in her low thoracic spine region. The normal MRI scan of the spine, the modified conduction studies and the albuminocytological dissociation of the CSF were consistent for AIDP. The Pegasis and Ribavirin treatment was interrupted and the patient received intravenous Immunoglobulin G. In the first days of the treatment the neurological status aggravated to tetraparesis with bilateral Bell's palsy. More to that point she became agitated and experienced vivid dream and visual hallucinations. The neurological symptomatology improved in the following days and the mental status abnormalities resolved after neuroleptic treatment. She recovered partially, after 6 weeks of intense neurological rehabilitation. We present a case of acute demyelinating polyneuropathy associated with neurosarcoidosis resulting in bi-brachial weakness. Case report: A 26-year-old man developed rapid onset of bi-brachial pain and weakness over 4 days. He could barely move his upper arms, forearms, and wrists, with minimal strength in the fingers (man-in-a-barrel). He had no other neurologic findings. The following were normal: CBC, serum chemistry, CK, viral hepatitis screen, heavy metals, ANA, RPR, HIV, lyme titer, and ACE. CSF showed glucose = 68 mg/dl, protein = 77 mg/dl, 1 WBC, 81 RBC; Albumin, IgG, and IgG index were marginally high, and no oligoclonal bands. NCV studies showed conduction slowing (26 to 42 m/s) and blocks in the upper-limb motor nerves with relative sparing of sensory nerves. He was treated with 5 days of IVIG with no improvement. Chest CT scans showed lymphadenopathies and biopsy revealed non-caseating granulomas and negative AFB consistent with sarcoidosis. He improved on high-dose prednisone and was able to raise both arms in one week, and in three months had 4/5 strength in the proximal muscles and 5/5 in the distal ones. Repeat NCV studies showed reversal of conduction blocks, although CVs remained slow. Discussion and conclusions: This is an unusual case of neurosarcoidosis presenting like Guillain-Barre syndrome (acute demyelinating polyneuropathy) based on the clinical, electrophysiological, and CSF features. Except that it did not respond with IVIG treatment and improved dramatically with high-dose corticosteroids. 
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